Treatment of achalasia – the current approach and personal experience

Czech version

Authors: E. Veseliny; P. Jarčuška; M. Zakuciová; L. Gombošová; M. Janičko
Authors‘ workplace: I. interná klinika LF UPJŠ a UNLP Košice
Published in: Gastroent Hepatol 2012; 66(2): 116-124
Category: Clinical and Experimental Gastroenterology: Review Article

Overview

Achalasia is a primary oesophageal motor disorder of unknown etiology. It is characterized by incomplete lower oesophageal sphincter (LES) relaxation and aperistalsis of the oesophageal body. The cause of the disease remains elusive and there is no intervention that improves the oesophageal body function. Because of that, treatment options remain strictly palliative. Current treatments aim to reduce distal oesophageal obstruction, facilitate oesophageal emptying and improve dilation of the oesophagus. The two most effective treatment options are graded pneumatic dilation and surgical myotomy. This multicenter, randomized, international trial has confirmed the similar efficacy of these treatments, at least in the short term. Owing to a lack of long-term benefit, endoscopic botulinum toxin injection and pharmacologic therapy are reserved for those who are unable to undergo more effective invasive therapies. Clinical predictors of the outcome, patient preferences and local expertise should be considered when making a decision on the most appropriate treatment option. The value of new endoscopic and radiologic techniques, such as peroral endoscopic myotomy and oesophageal stenting, has not been fully established.

Key words:
achalasia – pneumatic dilation – Heller myotomy – botulinum toxin – POEM

Sources

1. Francis DL, Katzka DA. Achalasia: update on the disease and its treatment. Gastroenterology 2010; 139(2): 369–374.

2. Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current understanding. Am J Gastroenterol 2005; 100(6): 1404–1414.

3. Dunaway PM, Wong RK. Risk and surveillance intervals for squamous cell carcinoma in achalasia. Gastrointestin Endosc Clin N Am 2001; 11(2): 425–434.

4. Cheatham JG, Wong RK. Current approach to the treatment of achalasia. Curr Gastroenterol Rep 2011; 13(3): 219–225.

5. Hoogerwerf WA, Pasricha PJ. Pharmacologic therapy in treating achalasia. Gastrointest Endosc Clin N Am 2001; 11(2): 311–324.

6. Bortolotti M, Mari C, Lopilato C et al. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology 2000; 118(2): 253–257.

7. Annese V, Bassoti G, Coccia G et al. Comparison of two different formulations of botulinum toxin A for the treatment of esophageal achalasia. Aliment Pharmacol Ther 1999; 13(10): 1347–1350.

8. Hoffman BJ, Knapple WL, Bhutani MS et al. Treatment of achalasia by injection of botulinum toxin under endoscopic ultrasound guidance. Gastrointest Endosc 1997; 45(1): 77–79.

9. Martínek J, Špičák J. A modified method of botulinum toxin injection in patients with achalasia: a pilot trial. Endoscopy 2003; 35(10): 841–844.

10. Pasricha PJ, Rai R, Ravich WJ et al. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology 1996; 110(5): 1410–1415.

11. Annese V, Bassotti G, Coccia G et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut 2000; 46(5): 597–600.

12. Martínek J, Široký M, Plottová Z et al. Treatment of patients with achalasia with botulinum toxin: a multicenter prospective cohort study. Dis Esophagus 2003; 16(3): 204–209.

13. Lake JM, Wong RK. Review article: the management of achalasia - a comparison of different treatment modalities. Aliment Pharmacol Ther 2006; 24(6): 909–918.

14. Vaezi MF, Richter JE. Diagnosis and management of achalasia. Practice guidelines. Am J Gastroenterol 1999; 94(12): 3406–3412.

15. Neubrand M, Scheurlen C, Schepke M et al. Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy 2002; 34(7): 519–523.

16. Bansal R, Nostrant TT, Scheiman JM et al. Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary achalasia. J Clin Gastroenterol 2003; 36(3): 209–14.

17. Hep A, Dolina J, Plottova Z et al. Is the complex therapy of achalasia by application of botulotoxin in combination with balloon dilatation a prospective approach? Bratisl lek listy 2000; 101(8): 433–437.

18. Kroupa R, Hep A, Dolina J et al. Combined treatment of achalasia –- botulinum toxin injection followed by pneumatic dilatation: long-term results. Dis Esophagus 2010; 23(2): 100–105.

19. Katzka DA, Castell DO. Use of botulinum toxin as a diagnostic/therapeutic trial to help clarify an indication for definitive therapy in patients with achalasia. Am J Gastroenterol 1999; 94(3): 637–642.

20. Wang L, Li YM, Li L. Meta-analysis of randomized and controlled treatment trials for achalasia. Dig Dis Sci 2009; 54(11): 2303–2311.

21. Spechler SJ. AGA technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology 1999; 117(1): 233–254.

22. Kadakia SC, Wong RK. Pneumatic balloon dilation for esophageal achalasia. Gastrointest Endosc Clin N Am 2001; 11(2): 325–345.

23. Martínek J, Kovacova S, Nosek V et al. Successful endoscopic treatment (clipping) of esophageal perforation during balloon dilatation in a patient with achalasia. Endoscopy 2008; 40 (Suppl 2): E61–62.

24. Hulselmans M, Vanuytsel T, Degreef T et al. Long-term outcome of pneumatic dilation in the treatment of achalasia. Clin Gastroenterol Hepatol 2010; 8(1): 30–35.

25. Richter JE. Update on the management of achalasia: balloons, surgery and drugs. Expert Rev Gastroenterol Hepatol 2008; 2(3): 435–445.

26. Zerbib F, Thétiot V, Richy F et al. Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia. Am J Gastroenterol 2006; 101(4): 692–697.

27. Dagli U, Kuran S, Savas N et al. Factors predicting outcome of balloon dilatation in achalasia. Dig Dis Sci 2009; 54(6): 1237–1242.

28. Alderliesten J, Conchillo JM, Leeuwenburgh I et al. Predictors for outcome of failure of balloon dilatation in patients with achalasia. Gut 2011; 60(1): 10–16.

29. Campos GM, Vittinghoff E, Rabl C et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg 2009; 249(1): 45–57.

30. Oelschlager BK, Chang L, Pellegrini CA. Improved outcome after extended gastric myotomy for achalasia. Arch Surg 2003; 138(5): 490–495.

31. Vaezi MF, Richter JE. Current therapies for achalasia: Comparison and efficacy. J Clin Gastroenterol 1998; 27(1): 21–35.

32. Rebecchi F, Giaccone C, Farinella E et al. Randomized controlled trial of laparoscopic Heller myotomy plus Dor fundoplication versus Nissen fundoplication for achalasia: long-term results. Ann Surg 2008; 248(6): 1023–1030.

33. Richards WO, Torquati A, Holzman MD et al. Heller myotomy versus Heller myotomy with Dor fundoplication for achalasia: a prospective randomized double-blind clinical trial. Ann Surg 2004; 240(3): 405–412.

34. Lovecek M, Gryga A, Herman J et al. Peroperative diagnostic methods during esophageal achalasia surgery. (Initial experience). Rozhl Chir 2003; 82(11): 566–569.

35. Kilic A, Schuchert MJ, Pennathur A et al. Long-term outcomes of laparoscopic Heller myotomy for achalasia. Surgery 2009; 146(4): 826–831.

36. Finley CJ, Kondra J, Clifton J et al. Factors associated with postoperative symptoms after laparoscopic Heller myotomy. Ann Thorac Surg 2010; 89(2): 392–396.

37. Gockel I, Junginger T, Eckardt VF. Persistent and recurrent achalasia after Heller myotomy: analysis of different patterns and long-term results of reoperation. Arch Surg 2007; 142(11): 1093–1097.

38. Wang L, Li YM, Li L et al. A systematic review and meta-analysis of the Chinese literature for the treatment of achalasia. World J Gastroenterol 2008; 14(38): 5900–5906.

39. Vela MF, Richetr JE, Khandwala F et al. The long-term efficacy of pneumatic dilatation and Heller myotomy for the treatment of achalasia. Clin Gastroenterol Hepatol 2006; 4(5): 580–587.

40. Boeckxstaens GE, Annese V, des Varannes SB et al. Pneumatic dilation versus laparoscopic Heller‘s myotomy for idiopathic achalasia. N Engl J Med 2011; 364(19): 1807–1816.

41. Pandolfino JE, Kwiatek MA, Nealis T et al. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology 2008; 135(5): 1526–1533.

42. Ortega JA, Madureri V, Perez L. Endoscopic myotomy in the treatment of achalasia. Gastrointest Endosc 1980; 26(1): 8–10.

43. Inoue H, Minami H, Kobayashi Y et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010; 42(4): 265–271.

44. Stavropoulos SN, Harris MD, Hida S et al. Endoscopic submucosal myotomy for the treatment of achalasia (with video). Gastrointest Endosc 2010; 72(6): 1309–1311.

45. Cheng YS, Ma F, Li YD et al. Temporary self-expanding metallic stents for achalasia: a prospective study with a long-term follow-up. World J Gastroenterol 2010; 16(40): 5111–5117.

46. Li YD, Cheng YS, Li MH et al. Temporary self-expanding metallic stents and pneumatic dilation for the treatment of achalasia: a prospective study with a long-term follow-up. Dis Esophagus 2010; 23(5): 361–367.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.